Globitair

Chinese drug iza-bren doubles lung cancer survival window in phase 3 trial

South China Morning PostPeople's Republic of China

Chinese drug iza-bren doubles lung cancer survival window in phase 3 trial

An anticancer drug developed by Sichuan Biokin Pharmaceutical took centre stage in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress in Madrid last week. Researchers said the drug, iza-bren, showed a significant advantage over platinum-based chemotherapy in a phase 3 randomised, double-blind clinical trial conducted at 73 hospitals in China and involving 432 patients with advanced lung cancer. The median progression-free survival (PFS) – the length of...

Read the full story at South China Morning PostOpen in the live monitor

Related discussion groups

No group discusses this yet. Start a discussion group and attach this story.

More news about People's Republic of China